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The announcement of laparoscopic laser cholecystectomy
in 1989 sparked a widespread interest in lasers and laser
technology.
1 Early proponents of laparoscopic cholecys-
tectomy described it as an operation to be performed with
a laser, and available literature suggested that laser energy
was necessary to accomplish laparoscopic gallbladder
removal. Indeed, in those early days, it seemed that
attempting laparoscopic cholecystectomy without a laser
engendered significant malpractice exposure as published
material stressed the use of lasers.
Teaching courses were quickly developed to meet the
intense demand for instructing almost 30,000 classically-
trained U.S. general surgeons in laparoscopic techniques.
Included in each course was a series of lectures on laser
physics and safety. The impetus to use lasers was further
compounded by the desire of laser companies to sell their
product and the public's fascination with lasers as "Star
Wars" technology.
A reasoned analysis of conditions during 1989-90 suggests
that the intense pressure placed on classically trained gen-
eral surgeons to adopt laparoscopic techniques precluded
an objective appraisal of the true role of lasers in surgery.
Lasers, as an energy source, were accepted uncritically and
many hospitals purchased expensive units that few had the
expertise to operate.
The blind acceptance of laser technology quickly turned to
rejection of that technology when it became apparent that
readily-available electrosurgical energy could perform
equally well in a laparoscopic environment.
2 The abrupt
rejection of lasers was emotional and visceral as general
surgeons felt misled by the laser companies and early advo-
cates of laser usage. Laser energy became "persona non
grata" after 1992 and the effect lingered for years.
Time and the application of scientific method, however, has
begun to separate the facts of laser subcellular interaction
from the fiction of uncritical application of laser power. An
examination of just four areas of investigation into laser
technology reveals that there is a sound basis for continued
exploration of laser energy in the treatment of human dis-
ease.
1) Low Intensity Laser Irradiation:
There have been many reports over the past two decades
of low intensity laser irradiation promoting tissue repair and
wound healing. The biologic basis of the laser's efficacy,
however, has not been completely elucidated.
Investigation into the precise biological processes involved
in low intensity laser irradiation is ongoing and includes:
a) The effect of laser irradiation on oxidative metabolism
of cells as evaluated by chemoluminescence measure-
ments.
b) The ability of laser light-stimulated cells to incorporate
tritiated thymidine as an indication of DNA synthesis.
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The use of these precise biological tools are now
revealing that wavelength-specific laser energy can
modulate tissue repair and wound healing.
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2) Thrombolytic Therapy:
Arterial obstruction is usually due to a combination of
plaque and thrombus. Some time ago, LaMuraglia showed
that thrombus absorbed more laser light (400 - 600 nm)
than vessel wall due to the presence of hemoglobin.
6 Since
the energy required to vaporize a clot in air is simple to
determine, it seemed that choosing a laser of the appropri-
ate wavelength would be sufficient to safely ablate throm-
bus. Laser ablation of a clot in a vessel containing flowing
liquid, however, is not the same as vaporizing that clot in
air. Early attempts at in vivo thrombus ablation not infre-
quently resulted in damage or perforation of the blood ves-
sel.
Recently, there has been laboratory investigation that mir-
rors the physical environment of blood vessels to examine
the underlying mechanics of thrombus ablation. One
model utilizes gelatin impregnated with a photostable
absorbing dye (to approximate the chromophore hemoglo-
bin) which is placed in a tube under water. A pulsed dye
laser at 577 nm is used to ablate the gelatin. This study has
suggested that thermal ablation need not be the dominant
mechanism in removal of a clot under liquid.
7 Rather, at
low energy settings, partial vaporization of the clot can
occur and cause mechanical expansion or collapse of a
vapor bubble. Mechanical action and not thermal vapor-
ization, therefore, can be the dominant factor in mass
removal under liquid. This model has also demonstrated
that temperatures need not exceed 100 degrees centigrade
to initiate the ablation process.
The ablation threshold for thrombus and vessel wall can be
predicted at any wavelength. Radiant exposure can be
chosen such that it is above the threshold for thrombus
ablation, but below that which causes thermal damage to
arterial plaque and vessel wall. More experimental work
needs to be done, but the unique preciseness of laser ener-
gy to remove clot is being explored in a rational manner.
3) Photodynamic Therapy (PDT):
Essentially, photochemical cellular destruction of a malig-
nancy is achieved by the combined action of a photosensitizer
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that accumulates in the tumor and light illumination in the
presence of tissue oxygen. There must, of course, be a suf-
ficient concentration of photosensitizer in the involved tis-
sue and light of the appropriate wavelength and energy
must be used to excite it.
Hematoporphyrin derivative or its purified ether/ester is
one of the most frequently used photosensitizers.
Prolonged skin photosensitization to this agent, however,
can be debilitating to the patient. In addition, more than
one layer of an organ may be sensitized, resulting in unde-
sirable injury to healthy tissue. To minimize these effects,
alternative methods to deliver the photosensitizer such as
intratumoral or intravesical delivery techniques have been
investigated.
5-aminolevulinic acid (ALA), is a naturally occurring pho-
toinactive intermediary in the cellular biosynthetic pathway
for the production of heme. During the production of
heme, ALA is converted to protoporphyrin IX (PpIX) and in
smaller amounts to coproporphyrin and uroporphyrin.
Protoporphyrin IX can be photosensitive.
Excess exogenous ALA instilled in a closed space such as
the urinary bladder can result in temporary excess accu-
mulation of PpIX. PpIX, which is photosensitive, can be
stimulated by light of the appropriate wavelength to cause
photochemical destruction of tumor.
Intravesical delivery of photosensitizer avoids, in part, the
build up of photosensitizer in adjacent tissues. In the case
of urinary bladder tumors, this method of delivery has been
shown to cause selective urothelial ablation without lamina
propria or detrusor muscle damage. This technique repre-
sents a significant refinement in the precise application of
laser energy to selectively destroy malignant tumor cells.
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4) Tissue Welding:
Tissue welding using laser energy has been around for
almost 20 years.
9 The potential benefits of this technique
are many and include the possibility of shorter operating
time, reduced foreign body reaction and scar, and the
potential to anastomose very small caliber vessels.
Laser tissue welding, however, has not been widely adopt-
ed. The main reasons for its lack of acceptance have been
the difficulty in predicting when tissue welding has
occurred and low weld strength during the initial healing
phase.
Tissue welding is a result of thermal coagulation of tissue
rather that a photochemical response. Laser irradiation
causes a disruption of cell membranes with leak of cellular
protein. A thermal degradation of the protein's disulfide
and hydroxyl bonds occurs which forms new molecular
bonds upon cooling, somewhat analogous to boiling an
egg.
During laser exposure, collagen is denatured and under-
goes swelling and reorganization of its fibrils in one direc-
tion. Protein that has leaked from the cells forms a micro
solder that, along with denatured collagen, forms a coagu-
lum. This coagulum results in tissue adhesion.
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Typically, the surgeon looks for a change in tissue color or
blanching to signify an end point for weld completion.
This parameter is highly subjective and lacks reproducibili-
ty in predicting the end point of tissue welding.
Recently, the two main disadvantages of laser welding tech-
niques have been addressed in unique ways.
First, it has been shown that efficient laser tissue welding
occurs at a surface temperature of 70 degrees centigrade.
Using a closed feedback loop consisting of an infrared ther-
mometer for tissue surface temperature measurement, and
a computer to manage temperature data acquisition and
laser power control, surface temperature can be maintained
at a constant value during tissue welding.
1
1 Secondly, it has
been found that human albumin solder can be used as a
vehicle for delivery of a biologically active recombinant
growth factor which is stable at the temperature necessary
for tissue welding. This growth factor, transforming growth
factor B1 (TGF-B1), has been shown to significantly accel-
erate wound healing.
1
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The use of temperature-controlled laser delivery techniques
affords a high degree of reproducibility and can be used to
prevent significant thermal degradation of the growth fac-
tor. The use of nonimmunogenic, inexpensive human
albumin permits the delivery of a single dose of growth fac-
tor which can be held at the wound site for extended peri-
ods and increase weld strength.
Conclusion:
Emotional overreaction of the general surgical community
to commercial exploitation of lasers in laparoscopic chole-
cystectomy has begun to subside. Laser energy is no longer
technology in search of a need, but rather a tool that the
scientist-surgeon can use in a precise and often times sub-
tle manner. The examples of investigational activity cited
demonstrate that the unique effects of laser energy on
human tissue are being explored in a sensible and rational
manner. The continued investigation of laser energy holds
promise for even more novel therapies to manage disease.
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